Claim Ledger
79% answered
Did management answer the analysts?
12 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →Dachepalli Publishers Ltd — Q3 FY26
Dachepalli Publishers reported Q3 FY26 total income of ₹14.78 crore and net profit of ₹1.44 crore, with a PAT margin of 9.78%.
bullish
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Dachepalli Publishers reported Q3 FY26 total income of ₹14.78 crore and net profit of ₹1.44 crore, with a PAT margin of 9.78%. The quarter is seasonally moderate due to the academic calendar, with 90% of revenue concentrated in Q4 and Q1. Management guided for full-year turnover of ₹90 crore, backed by confirmed orders of ₹25-30 crore. Growth drivers include expansion into four new states, a new e-commerce vertical (Pelican Edu Supply) targeting ₹30 crore from 50 schools, and new product launches (NCERT workbooks, financial literacy). The company plans to reach 25,000 schools in three years and targets ₹150 crore revenue next year. Key risk: execution of the D2C e-commerce ramp-up and inventory liquidation in a seasonal business.
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Customer Concentration Risk
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
School Count
10,000
N/A
Current presence in 10,000 schools; targeting 25,000 in 3 years.
E-commerce Revenue (Pilot)
₹2 crore
N/A
Pilot with 3 schools generated ₹2 crore; scaled to 50 schools targeting ₹30 crore.
Curriculum Integration Schools
60
+500% YoY
Increased from 10 schools last year to 60 this year; targeting 200 next year.
Repeat Customer Revenue Share
70%
N/A
70% revenue from repeat customers; expected to shift to 60:40 with new state expansion.
Fast read
Guidance and risk preview
Management confirmed full-year turnover of ₹90 crore, with confirmed orders of ₹25-30 crore already in hand.
Top 10 customers contributed significantly in FY25; management argues they are sticky due to 4-year prescription cycles, but concentration remains...
View Risks →